Role of Dynamic Contrast-enhanced MRI in Evaluating the Association Between Contralateral Parenchymal Enhancement and Survival Outcome in ER-positive, HER2-negative, Node-negative Invasive Breast Cancer

Overview

Journal J Magn Reson Imaging

Date 2018 May 8

PMID 29734483

Citations 10

Authors

Gi Won Shin

Yang Zhang

Min Jung Kim

Min-Ying Su

Eun-Kyung Kim

Hee Jung Moon

Jung Hyun Yoon

Vivian Youngjean Park

Affiliations

Soon will be listed here.

Abstract

Background: Background parenchymal enhancement (BPE) on dynamic contrast-enhanced (DCE)-MRI has been associated with breast cancer risk, both based on qualitative and quantitative assessments.

Purpose: To investigate whether BPE of the contralateral breast on preoperative DCE-MRI is associated with therapy outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.

Study Type: Retrospective.

Population: In all, 289 patients with unilateral ER-positive, HER2-negative, node-negative breast cancer larger than 5 mm.

Field Strength/sequence: 3T, T -weighted DCE sequence.

Assessment: BPE of the contralateral breast was assessed qualitatively by two dedicated radiologists and quantitatively (using region-of-interest and automatic breast segmentation).

Statistical Tests: Cox regression analysis was used to determine associations with recurrence-free survival (RFS) and distant metastasis-free survival (DFS). Interobserver variability for parenchymal enhancement was assessed using kappa statistics and intraclass correlation coefficient (ICC).

Results: The median follow-up time was 75.8 months. Multivariate analysis showed receipt of total mastectomy (hazard ratio [HR]: 5.497) and high Ki-67 expression level (HR: 5.956) were independent factors associated with worse RFS (P < 0.05). Only a high Ki-67 expression level was associated with worse DFS (HR: 3.571, P = 0.045). BPE assessments were not associated with outcome (RFS [qualitative BPE: P = 0.75, 0.92 for readers 1 and 2; quantitative BPE: P = 0.38-0.99], DFS, [qualitative BPE: P = 0.41, 0.16 for readers 1 and 2; quantitative BPE: P = 0.68-0.99]). For interobserver variability, there was good agreement between qualitative (κ = 0.700) and good to perfect agreement for most quantitative parameters of BPE.

Data Conclusion: Contralateral BPE showed no association with survival outcome in patients with ER-positive, HER2-negative, node-negative invasive breast cancer. A high Ki-67 expression level was associated with both worse recurrence-free and distant metastasis-free survival.

Level Of Evidence: 3 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2018;48:1678-1689.

Citing Articles

Are background breast parenchymal features on preoperative breast MRI associated with disease-free survival in patients with invasive breast cancer?.

Kim J, Kim J, Lee J, Lee N, Kim S, Nam K Radiol Med. 2024; 129(12):1790-1801.

PMID: 39496884 DOI: 10.1007/s11547-024-01914-8.

Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.

Ren Z, Pineda F, Howard F, Fan X, Nanda R, Abe H Magn Reson Imaging. 2023; 104:9-15.

PMID: 37611646 PMC: 10879456. DOI: 10.1016/j.mri.2023.08.003.

Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study.

Liu G, Xing Z, Guo C, Dai Q, Cheng H, Wang X Front Oncol. 2023; 13:1217869.

PMID: 37601676 PMC: 10436470. DOI: 10.3389/fonc.2023.1217869.

Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis.

Yoon J, Lee J, Yu M, Hur B, Grimm R, Sourbron S Eur Radiol. 2021; 32(1):34-45.

PMID: 34120229 DOI: 10.1007/s00330-021-08087-2.

Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.

Rella R, Contegiacomo A, Bufi E, Mercogliano S, Belli P, Manfredi R Br J Radiol. 2020; 94(1119):20200630.

PMID: 33035073 PMC: 8011258. DOI: 10.1259/bjr.20200630.

References

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Galea M, Blamey R, Elston C, Ellis I . The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22(3):207-19. DOI: 10.1007/BF01840834. View

Fisher B, Jeong J, Bryant J, Anderson S, Dignam J, Fisher E . Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004; 364(9437):858-68. DOI: 10.1016/S0140-6736(04)16981-X. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B . Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008; 10(4):R65. PMC: 2575538. DOI: 10.1186/bcr2124. View

Wiesner F, Magener A, Fasching P, Wesse J, Bani M, Rauh C . Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast. 2009; 18(2):135-41. DOI: 10.1016/j.breast.2009.02.009. View

Jansen S, Lin V, Giger M, Li H, Karczmar G, Newstead G . Normal parenchymal enhancement patterns in women undergoing MR screening of the breast. Eur Radiol. 2011; 21(7):1374-82. DOI: 10.1007/s00330-011-2080-z. View

Lin M, Chan S, Chen J, Chang D, Nie K, Chen S . A new bias field correction method combining N3 and FCM for improved segmentation of breast density on MRI. Med Phys. 2011; 38(1):5-14. PMC: 3017578. DOI: 10.1118/1.3519869. View

10.

King V, Brooks J, Bernstein J, Reiner A, Pike M, Morris E . Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology. 2011; 260(1):50-60. PMC: 6939979. DOI: 10.1148/radiol.11102156. View

11.

Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D . Quantification of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging. 2011; 33(5):1229-34. PMC: 3081108. DOI: 10.1002/jmri.22545. View

12.

Aleskandarany M, Green A, Benhasouna A, Barros F, Neal K, Reis-Filho J . Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012; 14(1):R3. PMC: 3496118. DOI: 10.1186/bcr3084. View

13.

King V, Gu Y, Kaplan J, Brooks J, Pike M, Morris E . Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol. 2012; 22(12):2641-7. DOI: 10.1007/s00330-012-2553-8. View

14.

Inwald E, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M . Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2):539-52. PMC: 3669503. DOI: 10.1007/s10549-013-2560-8. View

15.

Chen J, Yu H, Lin M, Mehta R, Su M . Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson Imaging. 2013; 31(9):1465-71. PMC: 3795886. DOI: 10.1016/j.mri.2013.07.014. View

16.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

17.

Kim S, Cho N, Ryu E, Seo M, Bae M, Chang J . Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery. Radiology. 2013; 270(3):699-707. DOI: 10.1148/radiol.13130459. View

18.

Lin M, Chen J, Wang X, Chan S, Chen S, Su M . Template-based automatic breast segmentation on MRI by excluding the chest region. Med Phys. 2013; 40(12):122301. PMC: 3843758. DOI: 10.1118/1.4828837. View

19.

Schrading S, Schild H, Kuhr M, Kuhl C . Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology. 2014; 271(1):45-55. DOI: 10.1148/radiol.13131198. View

20.

H M van der Velden B, Dmitriev I, Loo C, Pijnappel R, Gilhuijs K . Association between Parenchymal Enhancement of the Contralateral Breast in Dynamic Contrast-enhanced MR Imaging and Outcome of Patients with Unilateral Invasive Breast Cancer. Radiology. 2015; 276(3):675-85. DOI: 10.1148/radiol.15142192. View